RBR-3qfbw73招募中未知
A phase II,randomized, double-blind, placebo-controlled clinical study to evaluate the effectiveness, safety and tolerability of the Extract of the Pericarp of Passiflora edulis in the glycemic control of type 1 Diabetes Mellitus
niversidade Federal do Rio Grande do Norte0 个研究点开始时间: 2023年2月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 60Y（—）
入选标准
- •Both sexes aged between 18 and 60 years; type 1 diabetes mellitus diagnosis at least two years ago; absence of C-peptide; glycated hemoglobin between 7% and 10%; patients without significant changes in insulin dose (<10% of the number of daily units) in the last eight weeks; agreeing to participate in the trial by signing the informed consent form
排除标准
- •Illiterate; pregnant or breastfeeding; inability to follow research protocol; hypothyroidism; hyperthyroidism; Alzheimer's; Parkinson's; Schizophrenia; renal insufficiency; anemia; obesity (BMI> 30 kg /m2); hemoglobinopathy; acute liver disease; chronic liver disease; unit of alcohol per week: > 21 men and > 10 women; consumption of 1 or more cigarettes per day; phytotherapy; non-steroidal anti-inflammatory drugs, opiates and corticosteroids; juices or other foods based on passion fruit (P. edulis); food supplements containing passion fruit (P. edulis) in the composition
研究者
相似试验
进行中（未招募）
1 期
A phase 2 multi-centre study to evaluate the efficacy and safety of a chemokine CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy.MedDRA version: 15.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersDiabetic nephropathyEUCTR2012-003332-23-ESPfizer Inc., 235 42nd Street, New York, NY 10017, USA226
进行中（未招募）
1 期
A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with distal subungual onychomycosis.Distal subungual onychomycosisMedDRA version: 8.1Level: PTClassification code 10030338Term: OnychomycosisMedDRA version: 9.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2008-002418-23-ISStiefel Laboratories Inc.550
未知
2 期
A phase 2, randomized, double-blind, placebo-controlled, add-on study of DS-8500a in Japanese patients with type 2 diabetes mellitus receiving sitagliptiType 2 Diabetes MellitusJPRN-jRCT2080223082DAIICHI SANKYO CO., LTD.90
进行中（未招募）
不适用
A phase 2 multi-centre study to evaluate the efficacy and safety of a chemokine CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy.Diabetic nephropathyEUCTR2012-003332-23-ITPfizer Inc., 235 42nd Street, New York, NY 10017, USA176
进行中（未招募）
不适用
A phase 2 multi-centre study to evaluate the efficacy and safety of a chemokine CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy.Diabetic nephropathyEUCTR2012-003332-23-PLPfizer Inc., 235 42nd Street, New York, NY 10017, USA176